Skip to content

Clinical Validation of DACP Digital Design

Clinical Validation of DACP Digital Design

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03567005
Enrollment
60
Registered
2018-06-25
Start date
2018-06-25
Completion date
2018-08-26
Last updated
2019-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Errors

Brief summary

The purpose of this study is to evaluate the visual performance of DAILIES® AquaComfort Plus® (DACP) Digital lenses by assessing distance visual acuity (VA) as compared to DACP sphere contact lenses after one week of wear.

Interventions

DEVICENelfilcon A digital contact lenses

Silicone hydrogel digital contact lenses

Silicone hydrogel spherical contact lenses

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Willing and able to sign an IRB/IEC approved Informed Consent form; * Current wearer of DACP spherical contact lenses (at least 2 months in current correction), with a minimum wearing time of 5 days per week and 8 hours per day; * Experiencing symptoms of eye strain from using technology; * Willing to wear study lenses each day; * Possess spectacles that provide a corrected visual acuity of 20/40 or better in both eyes (OU) and be willing to wear them (as needed); * Willing to NOT use rewetting/lubricating drops at any time during the study; * Currently using digital devices (computer, tablet, and/or smart phone) for a minimum of 5 days per week and 4 hours per day; * Willing to NOT use any near aid (e.g. reading glasses) at any time during the study.

Exclusion criteria

* Conditions, use of medications, injury, or surgery, as specified in the protocol; * Wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment; * Monocular (only one eye with functional vision); * Pregnant.

Design outcomes

Primary

MeasureTime frameDescription
Distance Visual Acuity (VA) (logMAR, OU)Day 7, each productVA was tested under photopic (well-lit) conditions using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart positioned 6 meters from the subject. VA was collected bilaterally (OU) and measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower numeric value represents better visual acuity.

Secondary

MeasureTime frameDescription
Overall VisionDay 7, each productSubjective rating of overall vision on a scale of 1 (Poor) to 10 (Excellent). Both eyes contributed to the analysis.

Countries

United States

Participant flow

Recruitment details

Subjects were recruited from 5 investigative sites located in the United States.

Pre-assignment details

All 60 enrolled subjects were randomized and exposed to the investigational products.

Participants by arm

ArmCount
Overall
Nelfilcon A digital contact lenses and nelfilcon A contact lenses worn during Period 1 and Period 2 in a crossover assignment, as randomized.
60
Total60

Baseline characteristics

CharacteristicOverall
Age, Continuous25.2 years
STANDARD_DEVIATION 5.3
Race/Ethnicity, Customized
American Indian or Alaska Native
0 Participants
Race/Ethnicity, Customized
Asian
0 Participants
Race/Ethnicity, Customized
Black or African American
3 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
0 Participants
Race/Ethnicity, Customized
Other
1 Participants
Race/Ethnicity, Customized
White
56 Participants
Sex: Female, Male
Female
36 Participants
Sex: Female, Male
Male
24 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 600 / 60
other
Total, other adverse events
0 / 600 / 60
serious
Total, serious adverse events
0 / 600 / 60

Outcome results

Primary

Distance Visual Acuity (VA) (logMAR, OU)

VA was tested under photopic (well-lit) conditions using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart positioned 6 meters from the subject. VA was collected bilaterally (OU) and measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower numeric value represents better visual acuity.

Time frame: Day 7, each product

Population: Full Analysis Set with non-missing response

ArmMeasureValue (MEAN)Dispersion
DACP DigitalDistance Visual Acuity (VA) (logMAR, OU)-0.11 logMARStandard Deviation 0.1
DACPDistance Visual Acuity (VA) (logMAR, OU)-0.12 logMARStandard Deviation 0.09
Secondary

Overall Vision

Subjective rating of overall vision on a scale of 1 (Poor) to 10 (Excellent). Both eyes contributed to the analysis.

Time frame: Day 7, each product

Population: Full Analysis Set with non-missing response

ArmMeasureValue (MEAN)Dispersion
DACP DigitalOverall Vision8.8 units on a scaleStandard Deviation 1
DACPOverall Vision8.9 units on a scaleStandard Deviation 1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026